Sun Pharma
Sun Pharmaceutical Industries Ltd
- Market Cap
- ₹4,52,251 Cr
- P/E
- 41.25
Key Fundamentals
LargecapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 20.50%
- Debt to Equity
- 0.04
- EPS (TTM)
- ₹45.70
- Book Value
- ₹372.10
- Market Cap
- ₹4,52,251 Cr
- P/E (TTM)
- 41.25
- P/B
- 5.07
- ROE
- 16.00%
- Dividend Yield
- 0.84%
- EBITDA
- ₹19,703 Cr
- 52W High
- ₹2,046.90
- 52W Low
- ₹1,583.70
- Day Range
- ₹1,883.00 – ₹1,910.00
- Volume
- 19,16,054
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| 1,884.90 | 41.25 | 4,52,251 | 5.07 | 0.85% | 16.00% | 20.50% | 61,631 | 10,987 | |
| 11,180.50 | 88.26 | 2,96,807 | 16.49 | 0.27% | 16.50% | 22.00% | 12,191 | 3,363 | |
| 4,689.50 | 77.80 | 1,78,374 | 9.71 | 0.82% | 27.40% | 15.20% | 17,400 | 2,099 | |
| 2,294.60 | 92.52 | 1,23,980 | 20.45 | 0.04% | 18.30% | 17.80% | 7,823 | 1,332 | |
| 1,200.00 | 28.63 | 1,19,700 | 4.30 | 0.08% | 21.20% | 21.10% | 30,378 | 4,303 | |
| 1,390.20 | 41.44 | 1,16,037 | 2.99 | 0.57% | 11.20% | 13.00% | 33,097 | 2,760 | |
| 1,415.00 | 39.45 | 1,14,312 | 3.23 | 0.92% | 11.60% | 15.50% | 28,139 | 2,855 | |
| Median 7 companies | 1,884.90 | 41.44 | 1,23,980 | 5.07 | 0.57% | 16.50% | 17.80% | 28,139 | 2,855 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 55
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 68
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 30
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 82
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 22
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 31
- Poor
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 34.1%
Weaknesses
2- Promoter holding has decreased over last quarter: -1.80%
- The company has delivered a poor sales growth of 11.8% over past five years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 1 | 6 | 12 |
| Oscillators | Bullish | 0 | 6 | 3 |
| Moving Averages | Strong Bullish | 1 | 0 | 9 |
Oscillators
Bullish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 61.35
- Neutral
- MACD (12,26,9)
- 24.95
- Bullish
- SMA (50)
- 1,818.22
- Bullish
- SMA (200)
- 1,823.19
- Bullish
As of
Analyst Rating
28 of 32 analysts rate Buy, 1 Hold, 3 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +7.45% |
|---|---|
| 5Y | +11.78% |
| 3Y | +10.03% |
| 1Y | +11.19% |
| TTM | +12.13% |
Net profit
| 10Y | +7.36% |
|---|---|
| 5Y | +38.33% |
| 3Y | +10.57% |
| 1Y | +4.96% |
| TTM | +4.79% |
Operating cash flow
| 10Y | +6.39% |
|---|---|
| 5Y | +15.02% |
| 3Y | +35.80% |
| 1Y | −11.75% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −0.46 pp |
|---|---|
| 5Y | +2.94 pp |
| 3Y | +1.68 pp |
| 1Y | −0.52 pp |
| TTM | −0.81 pp |
Revenue by year
| Mar 2017 | ₹31,578 Cr |
|---|---|
| Mar 2018 | ₹26,489 Cr |
| Mar 2019 | ₹29,066 Cr |
| Mar 2020 | ₹32,838 Cr |
| Mar 2021 | ₹33,498 Cr |
| Mar 2022 | ₹38,654 Cr |
| Mar 2023 | ₹43,886 Cr |
| Mar 2024 | ₹48,497 Cr |
| Mar 2025 | ₹52,578 Cr |
| Mar 2026 | ₹58,462 Cr |
Net profit by year
| Mar 2017 | ₹7,846 Cr |
|---|---|
| Mar 2018 | ₹2,542 Cr |
| Mar 2019 | ₹3,208 Cr |
| Mar 2020 | ₹4,172 Cr |
| Mar 2021 | ₹2,272 Cr |
| Mar 2022 | ₹3,389 Cr |
| Mar 2023 | ₹8,513 Cr |
| Mar 2024 | ₹9,610 Cr |
| Mar 2025 | ₹10,965 Cr |
| Mar 2026 | ₹11,509 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Sun Pharmaceutical Industries Ltd trades at ₹1,880 as of 2026-11-13 with a market capitalization of ₹4,51,075 crore and a trailing PE of 41.14x. The company is virtually debt-free with a debt-to-equity ratio of 0.06, and has compounded profits at 17% over five years, though TTM profit growth has moderated to 7%.
- The company is nearly debt-free with a debt-to-equity ratio of just 0.06, providing significant financial flexibility and resilience against interest rate cycles.
- Five-year compounded profit growth of 17% demonstrates sustained earnings expansion over a meaningful period.
- ROCE of 17.94% indicates efficient deployment of capital, comfortably above typical cost-of-capital benchmarks for large-cap pharma companies.
- TTM sales growth of 12% shows continued top-line momentum, matching the five-year compounded sales growth rate of 12%.
- Consistent ROE averaging 16% over the last three and five years reflects reliable shareholder value creation, with the 10-year average at 14%.
- The company has maintained a healthy dividend payout ratio of 34.1%, balancing reinvestment with shareholder returns at a current yield of 0.85%.
- The stock has compounded at an 18% CAGR over five years and 17% over three years, reflecting sustained investor confidence and business momentum.
- A trailing PE of 41.14x is elevated relative to broader market averages, leaving limited room for earnings disappointment.
- TTM profit growth has decelerated sharply to 7%, down from the five-year compounded rate of 17%, signalling potential earnings growth fatigue.
- Promoter holding decreased by 1.80% in the last quarter, which can signal reduced insider confidence or dilution concerns.
- Price-to-book of 5.05x implies a rich premium to book value, which may compress if growth slows further.
- Ten-year compounded sales growth of only 7% suggests the underlying revenue trajectory has been modest over longer periods despite recent improvement.
- The stock trades roughly 8% below its 52-week high of ₹2,046.90, indicating the recent trend has turned from peak optimism.
- ROE of 13.79% on a trailing basis has dipped below the three-year and five-year averages of 16%, hinting at near-term return dilution.
- One-year stock CAGR of 7% lags the three-year and five-year CAGRs of 17% and 18% respectively, suggesting decelerating price momentum.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Sun Pharma's recent newsflow is largely procedural and governance-oriented, with no material headwinds surfacing. The ₹7,816 crore NCD raise and ESOP 2026 approval suggest the company is actively preparing capital for future growth. The appointment of Deloitte as auditors for a five-year term signals continued emphasis on governance. With upcoming investor meetings in mid-November, watch for fresh strategic or earnings guidance that could set the near-term tone.
- ESOP 2026 and borrowing limits approved Oct 31
Seven special resolutions passed via postal ballot on October 31, 2026, including a new ESOP 2026 plan and enhanced borrowing limits, signaling growth investment intent.
- ₹7,816 crore NCD allotment Oct 26
Completed private placement of ₹7,816 crore in non-convertible debentures on October 26, 2026, strengthening the company's capital base for expansion.
- Deloitte appointed as auditors Oct 30
Board approved Deloitte Haskins & Sells LLP as statutory auditors for five years from FY27 AGM, replacing SRBC & CO LLP, reinforcing governance standards.
- Investor meetings Nov 17-18 Nov 5
Sun Pharma will participate in analyst and institutional investor conferences in Mumbai on November 17-18, 2026.
- Q2FY27 earnings call recording live Oct 30
Audio recording of the Q2FY27 earnings call has been made available per SEBI regulations.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12,192 | 12,381 | 11,983 | 12,653 | 13,291 | 13,675 | 12,959 | 13,851 | 14,478 | 15,521 | 14,612 | 15,300 | 16,199 |
| Expenses | 9,013 | 8,904 | 8,948 | 9,045 | 9,352 | 9,666 | 9,243 | 9,550 | 9,951 | 10,572 | 10,658 | 10,882 | 11,455 |
| Operating Profit | 3,179 | 3,477 | 3,035 | 3,608 | 3,939 | 4,009 | 3,716 | 4,302 | 4,527 | 4,948 | 3,954 | 4,418 | 4,744 |
| OPM % | 26% | 28% | 25% | 29% | 30% | 29% | 29% | 31% | 31% | 32% | 27% | 29% | 29% |
| Other Income | 294 | 180 | 504 | 533 | 354 | 149 | 613 | 464 | 470 | 579 | 458 | 520 | 517 |
| Interest | 49 | 35 | 74 | 62 | 69 | 52 | 49 | 75 | 100 | 78 | 86 | 100 | 75 |
| Depreciation | 633 | 622 | 650 | 655 | 626 | 631 | 664 | 701 | 730 | 732 | 775 | 739 | 758 |
| Exceptional Items | — | — | — | — | — | — | −362 | −818 | — | −489 | — | — | −1,269 |
| PBT | 2,791 | 3,000 | 2,816 | 3,424 | 3,598 | 3,476 | 3,254 | 3,173 | 4,168 | 4,227 | 3,551 | 4,099 | 3,159 |
| Tax % | 14% | 14% | 5% | 16% | 16% | 16% | 34% | 27% | 25% | 20% | 23% | 29% | 37% |
| Net Profit | 2,385 | 2,561 | 2,659 | 2,861 | 3,037 | 2,913 | 2,154 | 2,293 | 3,125 | 3,381 | 2,710 | 2,901 | 1,995 |
| EPS (₹) | 9.90 | 10.52 | 11.06 | 11.82 | 12.67 | 12.10 | 8.96 | 9.50 | 13.00 | 14.04 | 11.31 | 12.06 | 8.29 |
| YoY Sales growth | 11 | 10 | 10 | 6 | 9 | 10 | 8 | 9 | 9 | 13 | 13 | 10 | 12 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 27,392 | 28,487 | 31,578 | 26,489 | 29,066 | 32,838 | 33,498 | 38,654 | 43,886 | 48,497 | 52,578 | 58,462 | 61,631 |
| Expenses | 19,498 | 20,313 | 21,476 | 20,858 | 22,689 | 25,855 | 25,028 | 28,397 | 32,235 | 35,479 | 37,464 | 41,961 | 43,567 |
| Operating Profit | 7,894 | 8,174 | 10,102 | 5,631 | 6,377 | 6,983 | 8,470 | 10,258 | 11,650 | 13,018 | 15,114 | 16,501 | 18,064 |
| OPM % | 29% | 29% | 32% | 21% | 22% | 21% | 25% | 27% | 27% | 27% | 29% | 28% | 29% |
| Other Income | 283 | −42 | 610 | −135 | −258 | 382 | −3,449 | −3,505 | 459 | 865 | 1,444 | 1,895 | 316 |
| Interest | 579 | 523 | 400 | 518 | 555 | 303 | 141 | 127 | 172 | 238 | 231 | 339 | 339 |
| Depreciation | 1,195 | 1,038 | 1,265 | 1,500 | 1,753 | 2,053 | 2,080 | 2,144 | 2,529 | 2,557 | 2,575 | 2,938 | 3,005 |
| PBT | 6,403 | 6,571 | 9,048 | 3,479 | 3,810 | 5,010 | 2,799 | 4,481 | 9,408 | 11,088 | 13,752 | 15,119 | 15,037 |
| Tax % | 14% | 14% | 13% | 26% | 16% | 16% | 18% | 24% | 9% | 13% | 20% | 24% | — |
| Net Profit | 5,476 | 5,658 | 7,846 | 2,542 | 3,208 | 4,172 | 2,272 | 3,389 | 8,513 | 9,610 | 10,965 | 11,509 | 10,987 |
| EPS (₹) | 21.92 | 18.89 | 29.03 | 8.73 | 11.11 | 15.69 | 12.10 | 13.64 | 35.32 | 39.91 | 45.55 | 47.84 | 45.70 |
| Div. Payout % | 14% | 5% | 12% | 23% | 25% | 25% | 62% | 73% | 33% | 34% | 35% | 33% | — |
| Sales growth | 70 | 4 | 11 | −16 | 10 | 13 | 2 | 15 | 14 | 11 | 8 | 11 | 12 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 207 | 241 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 |
| Reserves | 25,431 | 32,742 | 36,400 | 38,074 | 41,169 | 45,025 | 46,223 | 47,771 | 55,755 | 63,427 | 71,978 | 83,330 | 89,040 |
| Borrowings | 8,996 | 8,497 | 9,832 | 10,385 | 10,514 | 8,315 | 3,869 | 1,290 | 6,886 | 3,274 | 2,362 | 4,627 | 3,241 |
| Other Liabilities | 14,089 | 13,948 | 14,624 | 15,598 | 12,666 | 14,615 | 17,291 | 20,474 | 17,831 | 18,387 | 17,328 | 20,210 | 22,317 |
| Total Liabilities | 48,723 | 55,428 | 61,095 | 64,297 | 64,590 | 68,194 | 67,622 | 69,776 | 80,712 | 85,328 | 91,908 | 1,08,407 | 1,14,838 |
| Fixed Assets | 12,682 | 15,872 | 17,675 | 18,853 | 21,837 | 22,847 | 21,553 | 22,665 | 24,065 | 23,248 | 22,586 | 32,822 | 35,110 |
| CWIP | 2,039 | 2,175 | 2,801 | 2,465 | 1,411 | 1,220 | 1,567 | 1,287 | 4,973 | 5,354 | 6,644 | 3,052 | 1,864 |
| Investments | 2,716 | 1,830 | 1,192 | 7,143 | 7,903 | 10,143 | 9,612 | 12,849 | 14,824 | 15,026 | 18,354 | 24,723 | 16,449 |
| Other Assets | 31,286 | 35,550 | 39,427 | 35,837 | 33,439 | 33,984 | 34,890 | 32,975 | 36,849 | 41,700 | 44,324 | 47,811 | 61,415 |
| Total Assets | 48,723 | 55,428 | 61,095 | 64,297 | 64,590 | 68,194 | 67,622 | 69,776 | 80,712 | 85,328 | 91,908 | 1,08,407 | 1,14,838 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 5,616 | 6,686 | 7,082 | 3,907 | 2,196 | 6,555 | 6,170 | 8,985 | 4,959 | 12,135 | 14,072 | 12,419 |
| Investing | −1,502 | −3,949 | −4,186 | −3,104 | −310 | −2,225 | 407 | −5,556 | −7,220 | −763 | −5,183 | −10,405 |
| Financing | −1,187 | −1,889 | −2,285 | −1,539 | −2,731 | −5,715 | −5,980 | −5,193 | 2,376 | −6,710 | −7,906 | −2,513 |
| Net Cash Flow | 2,927 | 848 | 611 | −736 | −844 | −1,386 | 596 | −1,765 | 115 | 4,662 | 983 | −498 |
| Free Cash Flow | 3,316 | 3,353 | 3,492 | 2,013 | −966 | 5,105 | 5,097 | 7,550 | 2,895 | 9,964 | 12,005 | 8,906 |
| CFO/EBITDA | 93 | 106 | 90 | 83 | 48 | 113 | 85 | 78 | 56 | 105 | 96 | 89 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 87 | 83 | 108 | 112 | 105 | 99 | 99 | 95 | 85 | 91 | 97 |
| Inventory Days | 307 | 370 | 307 | 338 | 366 | 311 | 378 | 315 | 360 | 338 | 348 | 363 |
| Days Payable | 178 | 207 | 197 | 234 | 192 | 142 | 167 | 158 | 194 | 194 | 210 | 232 |
| Cash Conversion Cycle | 197 | 251 | 193 | 212 | 285 | 274 | 310 | 255 | 261 | 229 | 228 | 228 |
| Working Capital Days | −7 | 37 | −4 | −31 | 31 | 51 | 51 | 47 | 40 | 55 | 65 | 54 |
| ROCE % | 23% | 18% | 20% | 10% | 10% | 10% | 13% | 17% | 16% | 17% | 20% | 21% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sun Pharma insights
71 extracted metrics across FY07–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript Recording
- Concall · Oct 2026Recording
- Concall · Sep 2026PPT
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- 13 Oct 2026
- 13 Oct 2026
- 4 Aug 2026
- 6 May 2026
- 5 May 2026
- General announcements 5 Nov 2026
Frequently Asked Questions about Sun Pharma
What does Sun Pharmaceutical Industries Ltd do?
Where is Sun Pharmaceutical Industries Ltd (SUNPHARMA) listed?
Which sector does Sun Pharmaceutical Industries Ltd belong to?
What is the market capitalisation of Sun Pharmaceutical Industries Ltd?
What is the PE ratio of Sun Pharmaceutical Industries Ltd?
What is the 52-week high and low of Sun Pharmaceutical Industries Ltd?
Does Sun Pharmaceutical Industries Ltd pay dividends?
What is the Return on Equity (ROE) of Sun Pharmaceutical Industries Ltd?
Company Information
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SUNPHARMA.md for Sun Pharmaceutical Industries Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.